MONTIRELIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H24N6O4S
Molecular Weight	408.475
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1SC[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(N)=O

InChI

InChIKey=RSHMQGIMHQPMEB-IXOXFDKPSA-N

InChI=1S/C17H24N6O4S/c1-9-15(25)22-12(7-28-9)16(26)21-11(5-10-6-19-8-20-10)17(27)23-4-2-3-13(23)14(18)24/h6,8-9,11-13H,2-5,7H2,1H3,(H2,18,24)(H,19,20)(H,21,26)(H,22,25)/t9-,11+,12+,13+/m1/s1

HIDE SMILES / InChI

Description
Sources: Grünenthal (1997) Montirelin—A CNS Active TRH Analogue (Grünenthal GmbH, Aachen, Germany), pp 1–34. refernce retrieved from: | http://jpet.aspetjournals.org/content/305/2/410.full

NS-3 (montirelin, CG 3703) is an analog of thyrotrophin releasing hormone (TRH). More potent and longer acting than TRH, CG-3703 produced beneficial effects in animal models of concussion-induced unconsciousness, cerebral ischemia, memory disruption, spontaneous convulsions in rats, narcolepsy, and spinal trauma. Given its efficacy in these models, the potential indications were broadened to include seizures, nerve trauma, cognitive dysfunction, and sleep apnea.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thyrotropin-releasing hormone receptor 10 Target ID: Q01717 Gene ID: 25570.0 Gene Symbol: Trhr Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11833715	Agonist 2752		35.2 nM [Ki]
acetylcholine secretion 4 Target ID: GO:0061526 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7965809	Releasing Agent 8

Conditions

Condition	Modality	Highest Phase	Product
Cognition disorders 26 Sources: http://adisinsight.springer.com/drugs/800001824	Primary	Phase II 1147	Unknown Approved Use Unknown
Epilepsy 121 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8603636	Primary	Basic research	Unknown Approved Use Unknown
Disturbances of consciousness 2 Sources: Grünenthal (1997) Montirelin—A CNS Active TRH Analogue (Grünenthal GmbH, Aachen, Germany), pp 1–34. refernce retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/12606661	Primary	Phase III 665	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy.	2000-07	10869884
Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy.	1997-08-15	9236248
Effects of thyrotropin-releasing hormone and its analogue, NS-3, on blood pressure, heart rate, and serum catecholamine levels in rats.	1997-02	9013196
NS-3, a TRH-analog, reverses memory disruption by stimulating cholinergic and noradrenergic systems.	1996-02	8808149
NS-3(CG3703), a TRH analog, ameliorates scopolamine-induced memory disruption in rats.	1995-08	7675879
NS-3 (CG3703), an analog of thyrotropin-releasing hormone, ameliorates cognitive impairment in rats.	1995-04	7617693
Effect of NS-3, a thyrotropin-releasing hormone analog, on in vivo acetylcholine release in rat brain: regional differences and its sites of action.	1994-11	7965809
Differential affinities of TRH analogs at the mammalian spinal cord TRH receptor: implications for therapy in spinal injuries.	1989-09-25	2554219

Patents

Sample Use Guides

In Vivo Use Guide

0.5 mg of montirelin administered over 14 days improved ratings of global clinical state in 73% of patients exhibiting “disturbances of consciousness”.

Route of Administration: Unknown

In Vitro Use Guide

NS-3 (montirelin, CG 3703) is cytoprotective at 0.1-50 μM

Name

Type

Language

MONTIRELIN

Official Name

English

CG-3703

Preferred Name

English

CNK-602A

Code

English

montirelin [INN]

Common Name

English

N-(((3R,6R)-6-METHYL-5-OXO-3-THIOMORPHOLINYL)CARBONYL)-L-HISTIDYL-L-PROLINAMIDE

Systematic Name

English

NS-3

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C76367